Vemurafenib (PLX4032, RG7204)

Vemurafenib (PLX4032, RG7204)新しくて強力な阻害剤で、 B-RAFV600Eに作用すると、IC50 が 31 nMになる。

目録号S1267
5 5 7レビュー 23製品表彰状
価格 在庫  
USD 88 In stock
USD 114 In stock
USD 340 In stock
USD 970 In stock

Vemurafenib (PLX4032, RG7204) 化学構造
分子量: 489.92

品質と確認

カスタマーレビュー(7)

Quality Control & MSDS

製品情報

  • Combination Therapy
    併用療法
  • Compare Raf Inhibitors
    Raf阻害剤を比較
  • 研究分野
  • Vemurafenib (PLX4032, RG7204)のメカニズム

製品の説明

生物活性

情報 Vemurafenib (PLX4032, RG7204)新しくて強力な阻害剤で、 B-RAFV600Eに作用すると、IC50 が 31 nMになる。
目標 B-RafV600E C-Raf MAP4K5 (KHS1) SRMS ACK1 FGR
IC50 31 nM 48 nM 51 nM 18 nM 19 nM 63 nM [1]
In vitro試験 PLX4032 inhibits B-RAFV600E, C-RAF, as well as wildtype B-RAF, with IC50 of 31 nM, 48 nM and 100 nM, respectively. PLX4032 also inhibits several non-RAF kinases, including ACK1, KHS1, and SRMS, with IC50 of 18 nM to 51 nM. [1] In melanoma cell lines, the inhibitory effect by PLX4032 depends on B-RAF mutational status, because PLX4032 potently inhibits those harboring B-RAF V600 mutants, including V600E, V600D, V600K, and V600R, but not wildtype or other mutants. The IC50 values of PLX4032 on these cells, including MALME-3M, Colo829, Colo38, A375, SK-MEL28, and A2058, ranges from 20 nM to 1 μM. In these cells, PLX4032 (0.1 μM to 30 μM) also inhibits the phosphorylation of both MEK1/2 and ERK1/2. [2] PLX4032 is highly effective in the treatment of melanoma, for its ability of inhibiting B-RAFV600E. However, PLX4032 displays limited effect in colon cancer patients that also carrying B-RAFV600E oncoprotein. The reason for this is that, in colon cancer cells, B-RAFV600E inhibition by PLX4032 results in a rapid feedback EGFR activation, which compensates for the PLX4032-inhibited cell proliferation. [3]
In vivo試験 In B-RAFV600E-mutant mice xenograft models, PLX4032 (6 mg/kg–20 mg/kg) inhibits tumor growth. [1] In mice xenograft models of LOX, Colo829, and A375 cells, PLX4032 (12.5 mg/kg–100 mg/kg) inhibits tumor growth and prolongs mice survival. [2]
臨床試験 PLX4032 has recently been approved by US Food and Drug Administration (FDA) for the treatment of advanced metastatic melanoma with a B-RAFV600E mutation.
特集 A novel and potent inhibitor of the B-RAFV600E oncoprotein.

推薦された実験操作 (公開の文献だけ)

キナーゼアッセイ: [1]

RAF kinase activity measurements The kinase activities of wild-type RAF and mutants are determined by measuring phosphorylation of biotinylated-BAD protein. For each enzyme (0.01 ng), 20 μL reactions are carried out in 20 mM Hepes (pH 7.0), 10 mM MgCl2, 1 mM DTT, 0.01% (v/v) Tween-20, 50 nM biotin-BAD protein, and 1 mM ATP at room temperature. Reactions are stopped at 5 min with 5 μL of a solution containing 20 mM Hepes (pH 7.0), 200 mM NaCl, 80 mM EDTA, 0.3% (w/v) bovine serum albumin (BSA). The stop solution also includes phospho-BAD (Ser112) antibody, streptavidin-coated donor beads, and protein A acceptor beads. The antibody and beads are pre-incubated in stop solution in the dark at room temperature for 30 min. The final dilution of antibody is 1/2000 and the final concentration of each bead is 10 μg/mL. The assay plates are incubated at room temperature for one hour and then are read on a PerkinElmer AlphaQuest reader. Mutant activities are the average of two different batches of purified protein assayed in duplicate in three different experiments.

細胞アッセイ: [2]

細胞系 MALME-3M, Colo829, Colo38, A375, SK-MEL28, and A2058 cells
濃度 0–10 μM , dissolved in DMSO
処理時間 5 days
方法 Cellular proliferation is evaluated by MTT assay. Briefly, cells are plated in 96-well microtiter plates at a density of 1000 to 5000 cells per well in a volume of 180 μL. PLX4032 is prepared at 10 times the final assay concentration in media containing 1% DMSO. Twenty-four hours after cell plating, 20 μL of the appropriate dilution of PLX4032 are added to plates in duplicate. The plates are assayed for proliferation 6 days after the cells are plated. Percent inhibition is calculated and the IC50 is determined from the regression of a plot of the logarithm of the concentration versus percent inhibition.

動物実験: [2]

動物モデル Mice (athymic nude) xenograft models of LOX, Colo829, and A375 cells
製剤 Formulated as microprecipitated bulk powder (MBP), suspended at the desired concentration in an aqueous vehicle containing 2% Klucel LF, and adjusted to pH 4 with dilute HCl
投薬量 12.5 mg/kg–100 mg/kg
管理 Oral gavage twice daily
1

参考

化学情報

Download Vemurafenib (PLX4032, RG7204) SDF
分子量 489.92
化学式

C23H18ClF2N3O3S

CAS No. 918504-65-1
別名 RG7204
溶解度 (25°C)
  • DMSO 98 mg/mL
  • 水 <1 mg/mL
  • エタノール <1 mg/mL
保管 2年 -20°C
6月-80°Cin DMSO
化学名

研究分野

カスタマーレビュー (7)


Click to enlarge
Rating
Source J Invest Dermatol, 2013, ahead of print. Vemurafenib (PLX4032, RG7204) purchased from Selleck
Method Western blot
Cell Lines A375 melanoma cells
Concentrations 0-10 μM
Incubation Time 6 h
Results The activation of Stat3 and the protein expression of PAX3 were both repressed in vemurafenib-sensitive (parental) A375 and UACC62 melanoma cells, but higher vemurafenib concentration were required in resistant A375 and UACC62 melanoma cells. Specifically, vemurafenib at 1 μM inhibited the expression of phospho-Stat3 in sensitive cells, but not in resistant cells. These results suggest that inhibition of Stat3 signaling represents a potential therapeutic strategy to overcome the acquired resistance to vemurafenib in melanoma cells.

Click to enlarge
Rating
Source Oncoimmunology, 2012, 1(9), 1476-1483. Vemurafenib (PLX4032, RG7204) purchased from Selleck
Method flow cytometry
Cell Lines tumor-infiltrating lymphocytes
Concentrations 100-250 nM
Incubation Time 72 h
Results Treatment with Vem significantly increased the frequency of TILs recognizing autologous melanoma cells and responding to them by producing Type 1 helper cytokines (Fig. A ) or by mobilizing cytotoxic granules (Fig. B ), confirming the polyfunctionality of newly-induced responses.

Click to enlarge
Rating
Source J Invest Dermatol, 2011, 131(10), 2087-95.. Vemurafenib (PLX4032, RG7204) purchased from Selleck
Method Clonogenic assays
Cell Lines VM21/VM1 (c) cells
Concentrations 0.1 μM
Incubation Time 14 d
Results Combination of PD166866 with the V600E BRAF-specific inhibitor RG7204 (PLX4032) potently reduced clonogenic growth of VM21 and VM1 cells.

Click to enlarge
Rating
Source Vemurafenib (PLX4032, RG7204) purchased from Selleck
Method Western blot analysis/ In vitro colony formation assay
Cell Lines LOX IMVI melanoma cells
Concentrations 0-1 μM
Incubation Time 24 h
Results We therefore a ssessed the effe ct of the anti-E rbB3 anti-body A4 generated in our lab and able to inhibit the ligand-induced signaling and to potently induce receptor internalization and degradation, on vemurafenib-induced pErbB3 and pAKT levels and found that this was able to completely abrogate receptor phosphory l-ation and AKT signaling in all cell line s tested (Figure a)treatment with anti-ErbB3 mAb strongly potentiated growth inhibition by vemurafenib (Figure b and c). As expected only A3 but not A2 was able to completely abrogate vemurafenib-induced ErbB3 phosphorylation and AKT signaling (Figure d). Moreover in in vitro colony formation a ssays only A3 but not A2 strongly potentiated growth inhibition by vemurafenib(Figure e).

Click to enlarge
Rating
Source Dr Zhe-Sheng Chen of St. John's University. Vemurafenib (PLX4032, RG7204) purchased from Selleck
Method Cell cytotoxicity assay
Cell Lines HEK293 cells, HEK293/MRP7 cells
Concentrations 20 μM
Incubation Time
Results

Click to enlarge
Rating
Source Dr Zhe-Sheng Chen of St. John's University. Vemurafenib (PLX4032, RG7204) purchased from Selleck
Method Cell cytotoxicity assay
Cell Lines H460 cells, H460/MX20 cells
Concentrations 20 μM
Incubation Time
Results

Click to enlarge
Rating
Source Dr Zhe-Sheng Chen of St. John's University. Vemurafenib (PLX4032, RG7204) purchased from Selleck
Method [3H]-Mitoxantrone accumulation analysis
Cell Lines H460 cells, H460/MX20 cells
Concentrations 20 μM
Incubation Time 96 h
Results Vemurafenib increased the intra-cellular accumulation of Mitoxantrone in ABCG2 overexpressing H460/MX20 cells compared with parental H460 cells.

製品表彰状 (23)

  • Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. [Prahallad A, et al. Nature 2012;483(7387):100-3]

    PubMed: 22281684
  • MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling. [Huang S, et al. Cell 2012;151(5):937-50]

    PubMed: 23178117
  • MDM4 is a key therapeutic target in cutaneous melanoma. [Gembarska A, et al. Nat Med 2012;18(8):1239-47]

    PubMed: 22820643
  • Preexisting MEK1 Exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. [Shi H, et al. Cancer Discov 2012;2(5):414-24]

    PubMed: 22588879
  • A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. [Whittaker SR, et al. Cancer Discov 2013;3(3):350-62]

    PubMed: 23288408
  • Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. [Ohashi K, et al. Proc Natl Acad Sci U S A 2012;109(31):E2127-33]

    PubMed: 22773810
  • Characteristics of lung cancers harboring NRAS mutations. [Ohashi K, et al. Clin Cancer Res 2013;19(9):2584-91]

    PubMed: 23515407
  • Thyroid cancer cell resistance to gefitinib depends on the constitutive oncogenic activation of the ERK pathway [Frasca F,et al. J Clin Endocrinol Metab 2013;98(6):2502-12]

    PubMed: 23559083
  • Oncogenic B-RAF(V600E) Signaling Induces the T-Box3 Transcriptional Repressor to Repress E-Cadherin and Enhance Melanoma Cell Invasion. [Boyd SC, et al. J Invest Dermatol 2012;133(5):1269-77]

    PubMed: 23190890
  • Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition. [Metzner T, et al. J Invest Dermatol 2011;131(10):2087-95]

    PubMed: 21753785
  • Stat3-Targeted Therapies Overcome the Acquired Resistance to Vemurafenib in Melanomas [Liu F, et al. J Invest Dermatol 2013;133(8):2041-9]

    PubMed: 23344460
  • Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain. [Wagenaar TR, et al. Pigment Cell Melanoma Res 2013;27(1):124-33]

    PubMed: 24112705
  • Colloidal Aggregation Affects the Efficacy of Anticancer Drugs in Cell Culture. [Owen SC, et al. ACS Chem Biol 2012;7(8):1429-35]

    PubMed: 22625864
  • Aurora B is regulated by the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway and is a valuable potential target in melanoma cells. [Bonet C, et al. J Biol Chem 2012;287(35):29887-98]

    PubMed: 22767597
  • Melanoma Chemotherapy Leads to the Selection of ABCB5-Expressing Cells. [Chartrain M, et al. PLoS One 2012;7(5):e36762]

    PubMed: 22675422
  • Functional profiling of live melanoma samples using a novel automated platform. [Schayowitz A, et al. PLoS One 2012;7(12):e52760]

    PubMed: 23285177
  • Anti-Cancer Drugs Elicit Re-Expression of UDP-Glucuronosyltransferases in Melanoma Cells. [Dellinger RW, et al. PLoS One 2012;7(10):e47696]

    PubMed: 23110092
  • High iodine blocks a Notch/miR-19 loop activated by the BRAFV600E oncoprotein and restores the response to TGFβ in thyroid follicular cells. [Fuziwara CS, et al. Thyroid 2013;10.1089/thy.2013.0398]

    PubMed: 23998804
  • Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies. [Fattore L, et al. J Transl Med 2013;11:180]

    PubMed: 23890105
  • Specifically targeting ERK1 or ERK2 kills Melanoma cells. [Qin J, et al. J Transl Med 2012;10:15]

    PubMed: 22277029
  • The proteasome inhibitor bortezomib inhibits the growth of canine malignant melanoma cells in vitro and in vivo. [Keita Ito, et al. The Veterinary Journal 2013;198(3):577-82]

    PubMed: 24035468
  • Phenotypic Profiling of Raf Inhibitors and Mitochondrial Toxicity in 3D Tissue Using Biodynamic Imaging. [An R ,et al. J Biomol Screen 2013;10.1177/1087057113516674]

    PubMed: 24361645
  • BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer. [Donia M, et al. Oncoimmunology 2012;1(9):1476-1483]

    PubMed: 23264894

技術サポート&よくある質問(FAQ)

顧客がするかもしれない質問に対する答えは、指示を取り扱っている阻害剤で見つかります。話題は、貯蔵液(阻害剤と特別な注意を細胞ベースの分析法と動物のために必要とする問題を保存することは実験します)を準備する方法を含みます。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の問い合わせをするならば、メッセージを残してください。

* 必須

Related Raf 阻害剤

  • Sorafenib Tosylate

    Sorafenib Tosylateは、Raf-1、B-RafとVEGFR-2のマルチキナーゼ阻害剤で、IC50 がそれぞれ 6 nM、 22 nM、90 nMです。Phase 4

  • GDC-0879

    GDC-0879 は新型有効の選択B-Raf阻害剤、精製のB-RafV600E酵素や細胞p-ERKを作用すると、IC50がそれぞれ0.13 nM と 63 nMとなる.

  • PLX-4720

    PLX-4720は、B-Raf(V600E)とc-Raf-1(Y340D/Y341D)の「実行中の」形の強力で選択的な阻害剤で、IC50 がそれぞれ 13 nM と 6.7 nMです。

  • RAF265 (CHIR-265)

    RAF265 (CHIR-265)は内服生物の有効性のCRAF、WTBRAFとV600EBRAF阻害剤、IC50が3-60nMです。VEGFR2(IC50=30nM)、c-KitとPDGFRβも抑え、ただ抑制効果は少し弱い。

  • Raf265 derivative

    Raf265 derivative is a derivative of Raf265 that is an oral, highly selective RAF and VEGFR kinase inhibitor with IC50 of of 5 to 10 μM.

  • NVP-BHG712

    NVP-BHG712は、c-Raf、c-Srcとc-ablの特定の阻害剤で、IC50 がそれぞれ 0.395 μM、 1.266 μM と 1.667 μMです。

  • SB590885

    SB590885は、0.16nMのKiによる強力なB-Raf阻害剤です。

  • ZM 336372

    ZM 336372は、70nMのIC50による強力で選択的なc-Raf阻害剤です。

  • AZ 628

    AZ 628は力なチロシン・タンパク質阻害剤、 野生のタイプCRAFと BRAF V600Eに作用すると、 IC50 がそれぞれ 29 nM と 34 nMになる。

  • Dabrafenib (GSK2118436)

    Dabrafenib(GSK2118436)は、B-Rafの強力なATP競争的阻害剤で、 B-Raf、 B-RafV600E 、c-Rafに作用する時、 IC50 がそれぞれ 3.2 nM、 0.8 nM 、 5.0 nMです。

最近見られたアイテム

Tags: Vemurafenib (PLX4032, RG7204)を買う | Vemurafenib (PLX4032, RG7204)供給者 | Vemurafenib (PLX4032, RG7204)を購入する | Vemurafenib (PLX4032, RG7204)費用 | Vemurafenib (PLX4032, RG7204)生産者 | オーダーVemurafenib (PLX4032, RG7204) | Vemurafenib (PLX4032, RG7204)代理店
お問い合わせ